Xq. Xu et al., LOVASTATIN INHIBITS THE STIMULATION OF MITOGEN-ACTIVATED PROTEIN-KINASE BY INSULIN IN HIRCB FIBROBLASTS, Archives of biochemistry and biophysics, 326(2), 1996, pp. 233-237
Lovastatin, a cholesterol biosynthesis inhibitor, has recently been sh
own to inhibit mitogenesis and tumor growth, We have investigated the
effects of lovastatin on the activation of MAP kinase by insulin using
as a model HIRcB cells, a rat fibroblast cell line that overexpresses
the human insulin receptor, Treatment with lovastatin (1-30 mu M) for
24 h decreased the level of activation of MAP kinase by insulin by as
much as 60%, Immunoblotting experiments using a specific anti-MAP kin
ase monoclonal antibody demonstrated that the amount of MAP kinase pro
tein in the cells was not altered by lovastatin treatment, Likewise, l
ovastatin had no apparent effects on the expression of the insulin rec
eptor, Treatment with lovastatin (20 mu M) reduced the percentage of f
arnesylated Ras by 50%, Immunoprecipitation of tyrosine phosphorylated
proteins from HIRcB cell lysates followed by immunodetection of MAP k
inase using specific antibodies demonstrated a reduced level of insuli
n-induced tyrosine phosphorylation levels of MAP kinase in lovastatin-
treated cells, Furthermore, immunodetection of the beta-subunit of the
insulin receptor in anti-phosphotyrosine immunoprecipitates revealed
that treatment with lovastatin reduced the tyrosine phosphorylation le
vels of the receptor, Lysates obtained from cells treated with increas
ing concentrations of lovastatin demonstrated a dose-dependent inhibit
ion of the insulin-induced tyrosine phosphorylation of the receptor, T
reatment with mevalonic acid prevented the effects of lovastatin demon
strating that the effects of the drug are a consequence of its inhibit
ory effects on the synthesis of steroids, It is concluded that, in add
ition to inhibition of Ras farnesylation, lovastatin reduces receptor
tyrosine phosphorylation levels which also contributes to the blockade
of MAPK activation by the insulin receptor. (C) 1996 Academic Press,
Inc.